Diamyd Medical AB (publ)
Informe acción OM:DMYD B
Capitalización de mercado: SEK 1.4b
Salud financiera de hoja de balance de Diamyd Medical
Salud financiera controles de criterios 4/6 Diamyd Medical tiene un patrimonio de los accionistas total de SEK145.9M y una deuda total de SEK0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son SEK217.0M y SEK71.1M respectivamente.
Información clave Ratio de cobertura de intereses n/a Efectivo SEK 132.37m Patrimonio SEK 145.92m Total pasivo SEK 71.12m Activos totales SEK 217.04m
Actualizaciones recientes sobre salud financiera
Mostrar todas las actualizaciones
Diamyd Medical AB (publ), Annual General Meeting, Dec 05, 2024 Nov 06
Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Oct 09 Diamyd Medical AB (publ) to Report Q1, 2025 Results on Jan 29, 2025
CEO & President exercised options to buy kr660k worth of stock. Oct 04
Diamyd Medical to Pursue Accelerated Approval Pathway for Type 1 Diabetes Precision Medicine Sep 11
Diamyd Medical Announces Positive Interim Analysis Results for Phase 3 Trial in Type 1 Diabetes Jul 31
New major risk - Share price stability Jul 24
Third quarter 2024 earnings released Jun 27
Diamyd Medical AB (publ) to Report Q4, 2024 Results on Nov 14, 2024 Jun 26
Diamyd Medical AB (publ) Updates on the Registrational Phase 3 Trial May 17
Independent Chairman recently sold kr651k worth of stock Apr 29
Recruitment Milestone Reaches in Diamyd® Phase 3 Trial Apr 12
Second quarter 2024 earnings released Mar 28
New minor risk - Share price stability Feb 17
We're Keeping An Eye On Diamyd Medical's (STO:DMYD B) Cash Burn Rate Feb 02
First quarter 2024 earnings released Jan 25
In-Depth Analysis of Diamyd Medical AB (publ)'s Phase II Trial Further Supports Value of Presented Insulin Production Jan 24
Diamyd Medical's Precision Medicine Patent for the Prevention and Treatment of Autoimmune Diabetes Granted in South Korea Dec 07
Diamyd Medical AB (Publ) Elects Karin Rosén as A New Member of the Board Dec 01
Diamyd Medical AB (publ) to Report Fiscal Year 2023 Results on Nov 30, 2023 Nov 10
Chairman recently bought kr72k worth of stock Nov 05 Diamyd Medical AB (publ) has completed a Composite Units Offering in the amount of SEK 69.834709 million. Nov 02
Diamyd Medical AB (Publ) Announces Follow-Up Study Recommends Diamyd to Offer Advantages in Delivering Type 1 Diabetes Onset Oct 28
Diamyd Medical AB (publ) Announces Preliminary Results from Booster Trial with Diamyd Provide Additional Support for Intralymphatic Injection Oct 20 Diamyd Medical AB (publ) to Report Q2, 2024 Results on Mar 27, 2024
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Oct 11
Diamyd Medical AB (Publ) Announces Changes of the Board Oct 05
We Think Diamyd Medical (STO:DMYD B) Needs To Drive Business Growth Carefully Sep 22
Diamyd Medical AB (Publ) Announces Registrational Phase III Trial in Type 1 Diabetes with Diamyd Expands to the US Sep 06
New minor risk - Shareholder dilution Jul 09
Price target decreased by 27% to kr19.00 Jun 30 Diamyd Medical AB (publ), Annual General Meeting, Nov 30, 2023
Third quarter 2023 earnings released Jun 29
CEO & President recently bought kr88k worth of stock May 28
Second quarter 2023 earnings released Apr 06
Diamyd Medical Receives Patent Protection in the US and Japan for Gaba Formulation Remygen Feb 07
First quarter 2023 earnings released: kr0.43 loss per share (vs kr0.52 loss in 1Q 2022) Jan 26
Diamyd Medical Precision Medicine Patent for Prevention and Treatment of Autoimmune Diabetes to Be Granted in Eurasia Dec 08
Diamyd Medical AB (Publ) Announces US Partial Clinical Hold on Diamyd® Phase III Trial Lifted by the FDA Nov 27
Price target increased to kr19.50 Nov 16
Full year 2022 earnings released: kr1.35 loss per share (vs kr0.86 profit in FY 2021) Oct 06
All Patients in DIAGNODE-B Have Received an Additional (Booster) Injection of Diamyd Oct 02 Diamyd Medical AB (publ) to Report Q3, 2023 Results on Jun 28, 2023
Third quarter 2022 earnings released Jun 22 Diamyd Medical AB (publ), Annual General Meeting, Dec 01, 2022
Diamyd Medical AB (publ) Announces First Patient Enrolled in its Phase III Trial DIAGNODE-3 May 20
Price target increased to kr19.50 Apr 27
Director recently sold kr1.0m worth of stock Apr 15
Diamyd Medical AB Announces New Clinical Trial Will Evaluate an Additional Injection (Booster) with Diamyd Apr 14
Second quarter 2022 earnings: Revenues miss analyst expectations Mar 31
Clinical Trial in Type 1 Diabetes with Diamyd Medical's Remygen Is Fully Recruited Feb 09
Diamyd Medical Proceeds with Initiation of Type 1 Diabetes Phase III Trial in Europe Feb 07
First quarter 2022 earnings: Revenues miss analyst expectations Jan 27
Diamyd Medical AB Patent for Intralymphatic Injection of GAD in Autoimmune Diabetes to Be Granted in China Jan 19
Diamyd Medical Announces Australia Grants as the First Region Diamyd Medical A Broadening of A Patent for Intralymphatic Injection of Antigens in Autoimmune Diabetes Dec 24
Director recently sold kr3.7m worth of stock Dec 03
Diamyd Medical Pauses Start of Phase III Trial Dec 01
Investor sentiment deteriorated over the past week Nov 30
Full year 2021 earnings released: EPS kr0.86 (vs kr0.14 in FY 2020) Nov 17
CEO & President recently bought kr112k worth of stock Nov 08
CEO & President recently bought kr112k worth of stock Nov 04
Investor sentiment deteriorated over the past week Oct 20
Full year 2021 earnings released: EPS kr0.84 (vs kr0.14 in FY 2020) Oct 14
Diamyd Medical AB Receives First Regulatory Approval to Start the Phase III Trial DIAGNODE-3 with the Diabetes Vaccine Diamyd® Sep 23
Investor sentiment deteriorated over the past week Sep 20
Investor sentiment improved over the past week Sep 06
Third quarter 2021 earnings released Jun 25
Diamyd Medical AB (Publ) Announces 24-Month Follow-Up of Phase IIb Diamyd® Clinical Trial Indicates Continued Similar Progression After 15 Months Jun 17
Investor sentiment improved over the past week Jun 03
the 24-Month Follow-Up of DIAGNODE-2 with the Diabetes Vaccine Diamyd® Will Be Presented in Early July Apr 30
Director recently sold kr267k worth of stock Apr 26
Second quarter 2021 earnings released Mar 28
Diamyd Medical AB (publ) Announces Update on the design of a Phase III Precision Medicine trial with the Diabetes Vaccine Diamyd® Mar 05
Investor sentiment improved over the past week Mar 01
New 90-day low: kr25.25 Feb 25
Director recently sold kr1.2m worth of stock Feb 06
New 90-day low: kr26.00 Feb 04
What You Need To Know About Diamyd Medical AB (publ)'s (STO:DMYD B) Investor Composition Jan 22
Diamyd Medical AB Announces Positive Safety Evaluation of Remygen® in High Dose and in Combination with Alprazolam Gives the Go-Ahead for the Continuation of the Trial Jan 17
Meta-Analysis Updated with DIAGNODE-2 Results Provides Further Support for A Precision Medicine Approach Using Diamyd Medical Jan 12
New 90-day low: kr29.10 Jan 11
Diamyd Medical and Critical Path Institute Announce Data Sharing Collaboration to Develop Advanced Drug Development Tools in Type 1 Diabetes Dec 17
New 90-day low: kr30.20 Dec 14
Here's Why Diamyd Medical's (STO:DMYD B) Statutory Earnings Are Arguably Too Conservative Nov 30
Insider recently sold kr352k worth of stock Oct 22
Diamyd Medical AB (publ) Announces Operational Update About the Diabetes Vaccine Diamyd Oct 13 Diamyd Medical AB (publ) to Report Fiscal Year 2021 Results on Oct 06, 2021
Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (SEK159.1M) de DMYD B superan a sus pasivos a corto plazo (SEK40.0M).
Pasivo a largo plazo: Los activos a corto plazo de DMYD B (SEK159.1M) superan a sus pasivos a largo plazo (SEK31.1M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: DMYD B está libre de deudas.
Reducción de la deuda: DMYD B no ha tenido ninguna deuda en los últimos 5 años.
Análisis de cash runway En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: DMYD B tiene menos de un año de cash runway basado en su flujo de caja libre actual.
Pronóstico de cash runway: DMYD B tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 29.5% cada año
Descubre empresas con salud financiera Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
